Jeffrey M. Leiden

2015 - Vertex Pharmaceuticals

In 2015, Jeffrey M. Leiden earned a total compensation of $28.1M as Chairman, President & CEO at Vertex Pharmaceuticals, a 23% decrease compared to previous year.

Compensation breakdown

Non-Equity Incentive Plan$3,463,200
Option Awards$16,286,939
Salary$1,297,692
Stock Awards$7,038,885
Other$13,110
Total$28,099,826

Leiden received $16.3M in option awards, accounting for 57.96% of the total pay in 2015.

Leiden also received $3.5M in non-equity incentive plan, $1.3M in salary, $7M in stock awards and $13.1K in other compensation.

Overall ranking

Ranking

43

out of 13,593
Percentile100th

Jeffrey M. Leiden's 2015 compensation ranked 43rd out of 13,593 executive pay records tracked by us this year.

Leiden earned more than 99.7% of all executives tracked by us in 2015.

Ranking in industry group

Industry groupDrugs
Ranking

7

out of 1,485
Percentile100th

In the industry group of Drugs, Leiden's pay ranked 7th out of 1,485 executive pay records tracked by us in 2015.

Leiden earned more than 99.5% of executives in this group.

Source: SEC filing on April 28, 2017.

Leiden's colleagues

We found four more compensation records of executives who worked with Jeffrey M. Leiden at Vertex Pharmaceuticals in 2015.

2015

David Altshuler

Vertex Pharmaceuticals

Chief Scientific Officer

2015

Ian Smith

Vertex Pharmaceuticals

Chief Financial Officer

2015

Stuart Arbuckle

Vertex Pharmaceuticals

EVP & Chief Commercial Officer

2015

Jeffrey Chodakewitz

Vertex Pharmaceuticals

Chief Medical Officer

News

In-depth

You may also like